Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01829958 · ClinicalTrials.gov registry record · NA
Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy
A NA study of Diffuse Large B Cell Lymphoma (DLBCL) and Non Hodgkin Lymphoma (NHL), sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- NA
- Development phase
- 201
- Enrollment target
- 8
- Study locations
NCT01829958: Active NA study of Diffuse Large B Cell Lymphoma (DLBCL) and Non Hodgkin Lymphoma (NHL), sponsored by Memorial Sloan Kettering Cancer Center.
NCT01829958 is a NA study of Diffuse Large B Cell Lymphoma (DLBCL) and Non Hodgkin Lymphoma (NHL) that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 201 participants, below the 243-participant average among 10 other Diffuse Large B Cell Lymphoma (DLBCL) trials with a reported enrollment target (17% lower). The trial reports 8 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01829958, a NA study of Diffuse Large B Cell Lymphoma (DLBCL) and Non Hodgkin Lymphoma (NHL), is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 201 participants
- Enrollment target
- 8
- Study locations
Study Summary
This study will evaluate the ability of a largely self-administered geriatric assessment (GA) to predict toxicity in non-Hodgkin Lymphoma (NHL) patients ≥60 years old receiving chemotherapy or chemoimmunotherapy.
Primary Outcome
Hospitalization during or within 30 days following chemotherapy Dose delay or reduction to a dose intensity ≤80% of the planned dose intensity. Dose reductions occurring prior to cycle 1 of chemotherapy will be counted as events. Discontinuation of chemotherapy due to toxicity Grade 3 or higher non-hematologic toxicity Grade 4 or higher hematologic toxicity. Using the NCI CTCAE v4.0 toxicity grading
Conditions Studied
Interventions
- DRUG prednisone
- BEHAVIORAL Geriatric Assessment
- DRUG rituximab
Study Locations (8)
New York
- Memorial Sloan Kettering Commack - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Rockville Centre - Rockville Centre
- Memorial Sloan Kettering Nassau - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
- Memorial Sloan Kettering Bergen - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 201 participants |
| Start Date | 2013-04 |
| Est. Completion | 2026-04 |
| Phase | NA |
What the registry record for NCT01829958 still lists
NCT01829958 is an interventional study that assigns participants to a tested intervention. The registered 201 participants enrollment target is mid-sized for trials with a published cap, below the 243-participant average among 10 other Diffuse Large B Cell Lymphoma (DLBCL) trials with a reported enrollment target (17% lower).
The record links to 2 conditions, with Diffuse Large B Cell Lymphoma (DLBCL) appearing as the primary indexed condition, and to 3 interventions - of which prednisone is the first listed.
NCT01829958 lists 8 locations in 2 states (New York, New Jersey).
Frequently Asked Questions
What is clinical trial NCT01829958 about?
NCT01829958 is a clinical study titled "Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy". This study will evaluate the ability of a largely self-administered geriatric assessment (GA) to predict toxicity in non-Hodgkin Lymphoma (NHL) patients ≥60 years old receiving chemotherapy or chemoimmunotherapy.
What is the current status of trial NCT01829958?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 201 participants. The study started on 2013-04. Estimated completion is 2026-04.
What conditions does trial NCT01829958 study?
This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma (DLBCL), Non Hodgkin Lymphoma (NHL).
What interventions are being tested in trial NCT01829958?
The interventions under investigation include: prednisone (DRUG), Geriatric Assessment (BEHAVIORAL), rituximab (DRUG).
Who is sponsoring clinical trial NCT01829958?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01829958 being conducted?
This trial has 8 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diffuse Large B Cell Lymphoma (DLBCL)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01829958's enrollment target sits among peer trials
201 5th of 10 higher than 6 of 10 other Diffuse Large B Cell Lymphoma (DLBCL) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diffuse Large B Cell Lymphoma (DLBCL) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
RECRUITING · Phase 1
-
A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
RECRUITING · Phase 2
-
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
RECRUITING · Phase 3
-
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
RECRUITING · Phase 1
-
A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP
RECRUITING · Phase 2
-
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04422652 · 201 participants · Phase 2
Combination of Novel Therapies for CKD Comorbid Depression
- NCT05327114 · 201 participants · Phase 2
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- NCT06099769 · 201 participants · Phase 2
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
- NCT06274528 · 201 participants · Phase 2
DORA and LP in Alzheimer's Disease Biomarkers
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia